Rani Therapeutics Holdings (RANI) Other financing activities (2021 - 2026)
Rani Therapeutics Holdings (RANI) posted Other financing activities of $57000.0 for Q2 2026, up 1040.0% on a QoQ basis from $5000.0 in Q1 2026, and down 98.54% year-over-year from $3.9 million in Q2 2025.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Other financing activities (2021 - 2026) Analysis & Trends
Rani Therapeutics Holdings has reported Other financing activities for 6 years, with the latest figure at $57000.0 in Q2 2026.
- On a quarterly basis, Other financing activities fell 98.54% year-over-year to $57000.0 in Q2 2026; TTM through Jun 2026 was -$3.9 million, a 130.25% decrease from a year earlier, with the FY2025 full-year figure at $12000.0, down 76.47% from the prior year.
- Other financing activities was $57000.0 for Q2 2026 at Rani Therapeutics Holdings, up from $5000.0 in the prior quarter.
- The five-year high for Other financing activities was $8.9 million in Q3 2024, with the low at -$3.9 million in Q4 2025.
- Average Other financing activities over 5 years is $531352.9, with a median of $42000.0 recorded in 2025.
- The sharpest annual moves came in 2024 and 2025: Other financing activities soared 11288.46% in 2024, then slumped 7935.42% in 2025.
- Over 5 years, Other financing activities stood at -$148000.0 in 2022, then jumped by 72.97% to -$40000.0 in 2023, then declined by 20.0% to -$48000.0 in 2024, then plunged by 7935.42% to -$3.9 million in 2025, then surged by 101.48% to $57000.0 in 2026.
- The last three Other financing activities figures came in at $57000.0 (Q2 2026), $5000.0 (Q1 2026), and -$3.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 57,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | -3.86 Mn |
| Sep 30, 2025 | -68,000.00 |
| Jun 30, 2025 | 3.90 Mn |
| Mar 31, 2025 | 42,000.00 |
| Dec 31, 2024 | -48,000.00 |
| Sep 30, 2024 | 8.88 Mn |
| Jun 30, 2024 | -83,000.00 |
| Mar 31, 2024 | 121,000.00 |
| Dec 31, 2023 | -40,000.00 |
| Sep 30, 2023 | 78,000.00 |
| Jun 30, 2023 | -130,000.00 |
| Mar 31, 2023 | 132,000.00 |
| Dec 31, 2022 | -148,000.00 |
| Sep 30, 2022 | 145,000.00 |
| Jun 30, 2022 | 49,000.00 |
| Dec 31, 2021 | -570,000.00 |
| Mar 31, 2021 | 13,000.00 |